Highly active antiretroviral therapy (HAART) has modified the clinical course of human immunodeficiency virus (HIV) infection, reducing the rate of disease progression, the incidence of opportunistic infections and mortality. Several recent studies show early antiretroviral therapy reduces the risk of AIDS and HIV-related disease. The aim of this study was to perform an economic analysis to estimate the cost-utility of early antiretroviral therapy in Italy for managing HIV-infected patients.
Marcellusi, A., Viti, R., Russo, S., Andreoni, M., Antinori, A., & Mennini, F.S. (2016). Early treatment in HIV patients: a cost–utility analysis from the Italian perspective. CLINICAL DRUG INVESTIGATION, 36(5), 377-387 [10.1007/s40261-016-0382-2].